

1 **1. Title Page**

2 **Morphometric Analysis of Spina Bifida after Fetal Repair Shows New Subtypes with**
3 **Associated Outcomes**

4 Lovepreet K. Mann, MBBS¹, Shreya Pandiri, BS¹, Neha Agarwal, MD¹, Hope Northrup, MD², Kit
5 Sing Au, PhD², Elin Grundberg, PhD³, Eric P. Bergh, MD¹, Mary T. Austin, MD, MPH⁴, Rajan
6 Patel, MD⁵, Brandon Miller, MD, PhD⁴, Sen Zhu, PhD¹, Jonathan S. Feinberg, PhD¹, Dejian Lai,
7 PhD⁶, KuoJen Tsao, MD⁴, Stephen A. Fletcher, DO⁴, Ramesha Papanna, MD, MPH¹

8 ¹ Division of Fetal Intervention, Department of Obstetrics, Gynecology & Reproductive Sciences,
9 McGovern Medical School, UTHealth Science Center, Houston, TX 77030

10 ² Department of Pediatrics, McGovern Medical School, UTHealth Science Center, Houston, TX
11 77030

12 ³ Genomic Medicine Center, Department of Pediatrics, Children's Mercy Kansas City, Kansas
13 City, MO 64108

14 ⁴ Department of Pediatric Surgery, McGovern Medical School, UTHealth Science Center,
15 Houston, TX 77030

16 ⁵ Neuroradiology Section, Department of Radiology, Texas Children's Hospital, Houston, TX
17 77030

18 ⁶ Department of Biostatistics, School of Public Health, UTHealth Houston, Houston, TX

19

20 **Corresponding author:**

21 Lovepreet K. Mann, MBBS

22 6431 Fannin Street, Suite 3.274

23 Houston, TX 77030

24 Phone: 713-500-6423

25 FAX: 713-500-0799

26 Email: lovepreet.mann@uth.tmc.edu

27 and

28 Ramesha Papanna MD MPH

29 6431 Fannin Street, Suite 3.274

30 Houston, TX 77030

31 Phone: 713-500-5859

32 FAX: 713-500-0799

33 Email: ramesha.papanna@uth.tmc.edu

34 **Manuscript word count: 2969**

35 **2. Key Points**

36 **Question:** Are variations in spina bifida lesion morphology associated with clinical presentation
37 and outcomes?

38 **Findings:** This secondary analysis of intraoperative images and video from fetoscopic spina
39 bifida repair surgery distinguished five types of spina bifida lesion based on extent of nerve root
40 stretching and neural placode exposure. Preoperative fetal characteristics and postoperative
41 outcomes were significantly associated with lesion type.

42 **Meaning:** The novel classification of spina bifida to reveal a spectrum with clinical and research
43 implications.

44

45 **3. Abstract**

46 **Importance:** The binary classification of spina bifida lesions as myelomeningocele (with sac) or
47 myeloschisis (without sac) belies a spectrum of morphologies, which have not been correlated
48 to clinical characteristics and outcomes.

49 **Objective:** To characterize spina bifida lesion types and correlate them with preoperative
50 presentation and postoperative outcomes.

51 **Design:** Secondary analysis of images and videos obtained during fetoscopic spina bifida repair
52 surgery from 2020-2023.

53 **Setting:** Fetal surgery was performed at a quaternary care center.

54 **Participants:** A prospective cohort of patients referred for fetal spina bifida underwent
55 fetoscopic repair under an FDA-approved protocol. Of 60 lesions repaired, 57 had available
56 images and were included in the analysis.

57 **Intervention(s) or Exposure(s):** We evaluated lesion morphology on high-resolution
58 intraoperative images and videos to categorize lesions based on placode exposure and nerve
59 root stretching.

60 **Main Outcome(s) and Measure(s):** The reproducibility of the lesion classification was
61 assessed via Kappa interrater agreement. Preoperative characteristics analyzed include
62 ventricle size, tonsillar herniation level, lower extremities movement, and lesion dimensions.
63 Outcomes included surgical time, need for patch for skin closure, gestational age at delivery,
64 preterm premature rupture of membranes (PPROM), and neonatal cerebrospinal fluid (CSF)
65 diversion.

66 **Results:** We distinguished five lesion types that differ across a range of sac sizes, nerve root
67 stretching, and placode exposure, with 93% agreement between examiners ($p < 0.001$). Fetal

68 characteristics at preoperative evaluation differed significantly by lesion type, including lesion
69 volume ($p < 0.001$), largest ventricle size ($p = 0.008$), tonsillar herniation ($p = 0.005$), and head
70 circumference ($p = 0.03$). Lesion level, talipes, and lower extremities movement did not differ by
71 type. Surgical and perinatal outcomes differed by lesion type, including need for patch skin
72 closure ($p < 0.001$), gestational age at delivery ($p = 0.01$), and NICU length of stay ($p < 0.001$).
73 PPRM, CSF leakage at birth, and CSF diversion in the NICU did not differ between lesion
74 groups. Linear regression associated severity of ventriculomegaly with lesion type, but not with
75 tonsillar herniation level.

76 **Conclusions and Relevance:** There is a distinct phenotypic spectrum in open spina bifida with
77 differential baseline presentation and outcomes. Severity of ventriculomegaly is associated with
78 lesion type, rather than tonsillar herniation level. Our findings expand the classification of spina
79 bifida to reveal a spectrum that warrants further study.

80

81 **4. Introduction**

82 Spina bifida, the most common open neural tube defect in humans compatible with life,
83 develops when a fetus's neural tube fails to close within the first four weeks after conception.^{1,2}
84 The resulting lesion is conventionally typed as myelomeningocele or myeloschisis, based on the
85 presence or absence, respectively, of a cerebrospinal fluid (CSF)-filled sac over the open
86 neural tube.³ In myelomeningocele, this sac protects the covered portion of the spinal cord from
87 exposure to amniotic fluid but stretches the nerve roots. Both lesion types are characterized by
88 CSF leakage, and the developing central nervous system's exposure to amniotic fluid results in
89 hydrocephalus, hindbrain herniation (Chiari type II malformation), and consequent long-term
90 morbidity and mortality.⁴ These two lesion types represent a spectrum of morphologies,
91 however, as neural placode exposure to amniotic fluid in utero and nerve root stretching at the
92 lesion site vary by degree.³ Clinical features also vary, including severity of ventriculomegaly
93 and loss of lower extremities function.

94 Spina bifida's formation and effects have been explained by a two-hit hypothesis,
95 wherein the initial defect that prevents neural tube closure is followed by chemical or
96 mechanical damage to the exposed neural placode in utero.⁵ Reducing the placode's exposure
97 to amniotic fluid to minimize intrauterine damage and reverse hindbrain herniation provided the
98 rationale for repairing spina bifida prenatally.⁶ The randomized Management of
99 Myelomeningocele Study (MOMS) showed that patients who underwent prenatal surgery to
100 repair spina bifida needed ventriculoperitoneal shunting less often and had better spinal cord
101 function than those who underwent postnatal repair.⁷ Since MOMS, prenatal spina bifida repair
102 via open hysterotomy has become a widely accepted treatment option, and less invasive,
103 fetoscopic repair techniques have been tested with promising results.^{8,9} Nonetheless, children
104 who undergo in-utero spina bifida repair do not all benefit: in the MOMS cohort, 58% could not
105 ambulate independently at 30 months, and 68% needed shunt placement.⁷

106 Understanding the factors that contribute to this variability in long-term benefits after in-
107 utero spina bifida repair is essential to improving clinical outcomes. Although recent
108 retrospective studies have shown that fetal and neonatal motor function vary according to spina
109 bifida lesion type,^{3,10,11} a detailed typology of spina bifida lesions, characteristics and associated
110 outcomes is currently lacking.

111 In-utero repair provides an opportunity to directly visualize and assess spina bifida lesion
112 morphology midway through gestation. This study leveraged this opportunity to identify and
113 characterize a spectrum of spina bifida lesion types and correlate them with preoperative
114 presentation and postoperative outcomes.

115

116

117 **5. Methods**

118 **Study Design**

119 We conducted a secondary analysis of intraoperative images and video from fetoscopic spina
120 bifida repair surgery to identify lesion types based on morphology and correlate these types with
121 preoperative characteristics and postoperative outcomes.

122 **Study Population**

123 A prospective cohort of patients underwent fetoscopic spina bifida repair under approved
124 protocols between 2020 and 2023. Patients referred to the UTHealth Houston Fetal Center for
125 suspected fetal spina bifida underwent a comprehensive ultrasound evaluation, fetal magnetic
126 resonance imaging (fMRI), and multidisciplinary counseling. Fetoscopic in-utero spina bifida
127 repair was offered to those who met MOMS trial inclusion criteria,⁷ with maternal body mass
128 index (BMI) limit extended from 35 kg/m² to 45 kg/m² and amniotic fluid alpha fetoprotein higher
129 than 2.5 multiples of the median and positive for acetylcholinesterase to confirm CSF leakage
130 into the amniotic fluid. Eligible patients were offered participation in an institutional review board
131 (IRB)-approved spina bifida registry and an FDA- and IRB-approved trial studying the feasibility
132 of laparotomy-assisted fetoscopic spina bifida repair using a cryopreserved human umbilical
133 cord allograft as a meningeal patch (NCT06042140). Patients were counseled about risks,
134 benefits and alternatives, and informed consent was obtained before surgery. High-resolution
135 images and videos were collected during surgery per protocol. Patients with no images
136 available were excluded from this analysis.

137 **Preoperative evaluation**

138 Patients underwent ultrasound examinations by certified sonographers utilizing GE E8 and E10
139 (GE Voluson Expert Ultrasound Equipment; GE Healthcare Ultrasound, Milwaukee, WI)

140 systems. Lesions were measured in three dimensions: anterior-posterior (posterior vertebral
141 body surface to the sac surface), transverse (widest dimension of the sac) and vertical (cephalo-
142 caudad). In lesions with no sac, the vertical and transverse dimensions were measured from the
143 skin defect. The anterior-posterior dimension was measured as zero if there was no
144 displacement of the sac. Fetal lower extremity movements were evaluated, with normal
145 movements defined as any movement at the hips, knees, or ankles over 30 minutes. Right and
146 left lateral ventricles were measured in the posterior horn at the choroid plexus. Tonsillar
147 herniation was evaluated by fMRI per established methods.^{12,13}

148 **Fetoscopic spina bifida repair**

149 In-utero spina bifida repair was performed via laparotomy-assisted fetoscopic approach, using
150 cryopreserved human umbilical cord allografts (HUC-NEOX Cord 1K[®], Tissue Tech Inc, Miami,
151 FL) as a meningeal patch over the spinal placode, followed by skin closure (eMethods).¹⁴ If the
152 skin defect was too large to approximate the edges together, then a second HUC patch was
153 used for skin closure. Video and images were captured via high-resolution Hopkins[®] 45°
154 Telescope 5 mm (Karl Storz Endoscopy America, Inc.) used for visualization.

155 After surgery, patients recovered in hospital for 2-3 days. Patients stayed in Houston for
156 management at The Fetal Center or returned home for delivery. Neonatal care was managed
157 according to standard care.

158 **Outcomes**

159 Duration of surgery and need for patch skin closure were recorded. Perinatal outcomes included
160 gestational age at delivery, preterm premature rupture of membranes (PPROM), and CSF
161 diversion in the neonatal intensive care unit (NICU) (at the pediatric neurosurgeon's discretion).
162 For patients who delivered outside The Fetal Center, perinatal outcomes were collected by
163 delivery record review and calls to patients.

164 **Lesion classification**

165 By reviewing intraoperative images and videos, we distinguished five lesion types based on
166 nerve root stretching and placode exposure (Figure 1).

- 167 • **Type 1:** Large sac, neural placode displaced from the spinal canal and attached to the
168 highest portion of the protruded thecal sac. Central canal is open through a small
169 opening with skin and meningeal coverage of the sac. Minimal neural placode exposure
170 to amniotic fluid. Nerve roots are stretched from the spinal canal.
- 171 • **Type 2:** Large sac, the placode displaced from the spinal canal to the highest portion of
172 the protruded thecal sac. The placode is open for more than half the lesion's vertical
173 length, with direct exposure to amniotic fluid. Nerve roots are stretched from the spinal
174 canal.
- 175 • **Type 3:** Like Type 2, but less placode displacement and less nerve root stretching. The
176 placode is open less than half the lesion's vertical length, with less exposure to amniotic
177 fluid.
- 178 • **Type 4:** The placode is not displaced from the vertebral canal, and nerve root stretching
179 is minimal. The placode is open, but some meningeal coverage reduces exposure to
180 amniotic fluid.
- 181 • **Type 5:** Like Type 4, but no meningeal coverage. The placode is completely exposed to
182 amniotic fluid. Nerve roots are not stretched from the spinal canal.

183 The primary reviewer (RP) classified each lesion retrospectively based on these criteria. Then, a
184 second reviewer (LKM) independently classified each lesion by the same criteria for
185 reproducibility. Both were blinded to preoperative and postoperative findings and outcomes.
186 Disagreement cases are presented in the Results.

187

188 **Statistical Analysis**

189 Data were analyzed and visualized in R using ggpubr and ggplot2 packages. Descriptive, then
190 inferential statistics were reported. We derived the semi-ellipsoid lesion volume by the equation,
191 $V = \pi * \frac{4}{3} * A * B * C$, where A, B, and C are lesion dimensions. Due to non-normally distributed
192 data, the Kruskal-Wallis test was performed. Mann–Whitney U test for multiple comparisons
193 was used for post hoc analysis to determine significant main effects. Categorical data were
194 compared via Fisher’s Exact test. Interrater agreement for lesion types was assessed using
195 kappa statistics. Preoperative ventricle size and its association with lesion type, tonsillar
196 herniation and lesion level were evaluated via linear regression in SAS (9.4, Cary, NC).

197

198

199 **6. Results**

200 Of 60 spina bifida lesions repaired fetoscopically at The Fetal Center from 2020–2023, 57 had
201 high-quality images available. Forty-eight patients were enrolled through an FDA feasibility
202 study; nine were enrolled as practice of medicine cases in an observational cohort study.
203 Nineteen patients delivered outside The Fetal Center.

204 **Lesion classification**

205 Lesion types 1 through 5 accounted for 14%, 39%, 16%, 14%, and 18%, respectively, of the
206 lesions in our cohort (Table 1). Reviewers classified lesions with 93% agreement ($p < 0.001$).
207 They disagreed in three cases: Type 4 and Type 5; Type 2 and Type 3; Type 2 and Type 5. The
208 third disagreement case was reviewed: the second reviewer's interpretation was affected by the
209 angle of the lesion image. The primary reviewer's classification was selected for the final
210 analysis in all cases.

211 **Preoperative characteristics**

212 Maternal demographics did not differ between lesion groups, nor did fetal extremity movement,
213 lesion level, or talipes (Table 1). Estimated fetal weight (EFW) did not differ by lesion type when
214 considered as an aggregate measure, but analysis of EFW's subcomponents found significant
215 differences in head circumference (HC) by lesion type ($p = 0.03$): fetuses with Type 2 lesions had
216 a higher percentile HC than those with Types 4 ($p < 0.05$) and 5 ($p < 0.001$), and those with Types
217 1 and 3 had a higher percentile HC than those with Type 5 ($p < 0.01$) (Figure 2).

218 Lesion dimensions differed by type (Table 1; eFigure 1). Type 1 lesions were
219 significantly larger than all other types in all three dimensions and in volume. Type 2 lesions
220 were longer than Type 3 vertically and larger than Types 3-5 in the anterior-posterior and
221 transverse dimensions and in volume. Type 3 was wider than Type 4 and larger than Type 5 in
222 the anterior-posterior and transverse dimensions and in volume.

223 Largest ventricle size differed by lesion type ($p=0.0074$), as fetuses with Type 2 lesions
224 had larger ventricles than those with Types 1, 4, and 5 (Table 1, Figure 2). Right ($p=0.017$) and
225 left ($p=0.0058$) ventricle sizes differed similarly by lesion type: Type 2 had larger right ventricles
226 than Types 1 and 4 and larger left ventricles than Types 1, 4, and 5 (Table 1; eFigure 2A, 2C).
227 When adjusting for HC, Type 2 had larger right and left ventricles than Types 1 and 4; Type 5
228 had larger right ventricles than Type 4 and larger left ventricles than Types 1 and 4 (eFigure 2B,
229 2D).

230 **Ventricle size is associated with lesion type**

231 We evaluated the association between ventricle size and lesion type, lesion level, and tonsillar
232 herniation via linear regression. Conditioning on the lesion level and tonsillar herniation
233 (foramen magnum or above: mild; C1-C2: moderate; C3-C4: severe), largest ventricle size is
234 significantly associated with lesion type (Table 2). Specifically, largest ventricle is greater in
235 Type 2 than in Type 5 lesions ($p=0.008$). Fetuses with lower lesion levels had smaller ventricles,
236 but this was not statistically significant ($p=0.07$).

237 **Surgical and neonatal outcomes**

238 All 10 (100.0%) Type 5 lesions required skin patch closure, which differed from all other lesion
239 types ($p<0.001$). Surgical time and gestational age at surgery did not differ between groups, nor
240 did PPROM, CSF leakage at birth, wound revision, or CSF diversion in the NICU (Table 3).

241 Neonates with Type 1 lesions were delivered at an earlier gestational age than those
242 with Types 2, 3, and 5; those with Type 4 lesions were delivered earlier than those with Type 2
243 (Table 3, eFigure 3A). Neonates with Type 2 and 3 lesions required fewer days in the NICU
244 than those with Types 1 and 4; Type 2 also had fewer NICU days than Type 5 ($p<0.001$)
245 (eFigure 3B).

246

247 **Cortical Index from baseline to delivery**

248 Despite significant differences in HC percentile at baseline among lesion groups ($p=0.0015$), HC
249 percentile at delivery did not differ by lesion type ($p=0.12$) (Figure 2). By contrast, largest
250 ventricle size at last ultrasound (within four weeks of delivery; $n=49$) differed by lesion type
251 ($p=0.028$): Type 2 had larger ventricles than Types 1 and 5. Analysis of the change in HC
252 percentile from baseline to delivery found a marked increase among those with Type 5 lesions
253 ($p=0.002$). Types 2–4 increased in HC, but not statistically significantly. Ventricle size increased
254 in Types 2 ($p=0.00011$), 3 ($p=0.0039$), and 5 ($p=0.0059$).

255 To determine the extent to which the increase in HC from baseline to delivery reflects
256 cortical development versus ventricle growth, we calculated the Cortical Index (CI) by dividing
257 HC (in mm) by ventricle diameter (in mm).¹⁵ CI at baseline differed significantly by lesion type
258 ($p=0.0077$): Type 2 had a lower CI than Types 1 and 4, consistent with ventricular differences.
259 CI before delivery did not differ by lesion type ($p=0.073$). CI increased from baseline in Type 5
260 ($p=0.02$), but not in other lesion groups (Figure 2).

261

262 **7. Discussion**

263 Spina bifida is conventionally classified as myelomeningocele or myeloschisis, based on the
264 presence or absence, respectively, of a sac covering the open neural tube.¹⁰ However, our
265 clinical observations from performing spina bifida repair at a high-volume center suggested a
266 range of lesion morphologies inconsistent with a binary classification. Clinical features, fetal
267 anatomy, and postnatal outcomes also vary considerably. Understanding the factors that
268 contribute to this variability requires a more complex classification of spina bifida lesion types
269 and their association with preoperative presentation and postoperative outcomes. As a step
270 toward that classification, we evaluated intraoperative images and videos, and we distinguished
271 five types of spina bifida lesions based on nerve root stretching and neural placode exposure.
272 Fetal characteristics at baseline evaluation, including head circumference and ventricle size,
273 differed significantly by these lesion types. Operative and perinatal outcomes, including need for
274 patch skin closure, gestational age at delivery, and length of NICU stay, also differed by lesion
275 type. Collectively, these findings suggest a spectrum of spina bifida types that warrants further
276 characterization. These findings are potentially significant for clinical practice, as understanding
277 the range of spina bifida presentations and their associated outcomes would inform patient
278 counseling and surgical planning.

279 In the study, lesion type was the most important association factor for ventriculomegaly,
280 with Type 2 having the largest ventricular diameter. However, there was no association between
281 ventricle size and tonsillar herniation level. This differs from the common understanding that
282 hindbrain herniation obstructing cerebrospinal fluid flow through the foramen Luschka and
283 Magendie in the fourth ventricle contributes to ventriculomegaly.¹⁹ Future studies in a larger
284 cohort would allow group analyses of the relation between ventricle size, lesion level, and
285 hindbrain herniation within each lesion type.

286 Our analysis of fetal characteristics and perinatal outcomes by lesion type revealed
287 significant gains in head circumference (HC), from around the 5th to the 75th percentile, among
288 those with Type 5 lesions. That group's corresponding increase in Cortical Index (CI), reflecting
289 faster growth of HC than of ventricles, suggests that the changes in HC are not attributable to
290 ventriculomegaly alone and may indicate cortical mass development after in-utero spina bifida
291 repair. Similarly, Danzer et al. reported fetal head biometry changes with increases in CI after
292 in-utero repair in 50 fetuses.¹⁵ In our cohort, fetuses with lesion Types 2-4 also showed
293 increases in HC from baseline to delivery, but these were not statistically significant, nor did CI
294 change significantly in those groups. One possible explanation is that fetuses with Type 2-4
295 lesions may have narrowing of the cerebral aqueduct that does not improve with in-utero spina
296 bifida repair. Other recent analyses have reported differences in motor function between
297 different lesion types. Oliver et al.'s review of 404 patients found that myelomeningocele lesions,
298 whether repaired prenatally or postnatally, are associated with fetal talipes and impaired lower
299 extremities movement.³ Corroenne et al. reported that fetuses with myeloschisis were 3.1 times
300 more likely to have intact motor function prenatally¹⁰ and 11.2 times more likely to have intact
301 motor function at birth.¹¹ Farmer et al.'s study of pediatric outcomes in the MOMS cohort
302 reported that absence of a sac covering the lesion was associated with independent ambulation
303 at 30 months among patients who underwent prenatal surgery.¹⁸ The extent to which
304 differences in presentation and outcomes across lesion types reflect anatomical variations
305 versus response to therapy or other factors requires further investigation. The lack of significant
306 findings in several of the lesion types could be due to the smaller sample sizes in those types.
307 Larger studies are needed to further explain these findings.

308 Our demonstration of a broader spectrum of lesion types than previously assumed may
309 have implications for future molecular studies, allowing insight into genetic and epigenetic
310 mechanisms contributing to lesion development. Spina bifida is believed to be highly heritable,

311 but its complex etiology, rarity in the population and phenotypic heterogeneity make variant
312 detection and gene/pathway discovery challenging. Studies have identified deleterious genomic
313 variants that may increase the risk for developing spina bifida.^{20,21} Others have demonstrated
314 the importance of studying the genomic and transcriptomic profiles of spina bifida lesions.²²⁻²⁴
315 Nonetheless, further studies are needed to explore the molecular basis for variations in spina
316 bifida lesion formation and its clinical implications.

317 Our study's major strength is its prospective, consistent data collection under an FDA
318 clinical trial protocol. All surgeries were performed at a single, high-volume center, thus ensuring
319 procedural consistency. Our study population was recruited under broad inclusion criteria
320 comparable to the MOMS trial. We confirmed the interrater reliability of our classification
321 between two independent reviewers. This study was limited by a small sample size not powered
322 to compare differences between groups that were not significant, such as lower extremities
323 movement. The lesion types of those not offered prenatal surgery may differ from those who
324 underwent surgery. Differences in neonatal management across centers may have affected
325 outcomes for patients who delivered outside The Fetal Center. There was no identifiable reason
326 for preterm birth in the Type 1 group. This needs further evaluation in a larger cohort.

327 **Conclusions**

328 Direct visualization of spina bifida lesions during fetoscopic repair surgery distinguished five
329 types of spina bifida that differ with respect to nerve root stretching and neural placode
330 exposure to amniotic fluid. These types may have implications for baseline function and
331 prognosis. Further research is needed to explore the molecular basis for variations in spina
332 bifida formation and response to in-utero therapy.

333 **8. Acknowledgements**

334 Lovepreet K. Mann and Ramesha Papanna had full access to all the data in the study and take
335 responsibility for the integrity of the data and the accuracy of the data analysis. The authors
336 would like to acknowledge Arthur Day, MD, Bradley E. Weprin, MD and John Honeycutt, MD for
337 their assessments, as independent pediatric neurosurgeons, of the completeness of the surgical
338 closure for the FDA IDE study.

339 **Disclosure:** The authors declare no competing financial interest.

340 **Funding source:** Lovepreet K. Mann's, Stephen A. Fletcher's and Ramesha Papanna's efforts
341 for this project were partially funded by NICHD (1R01HD105173).

342

343

344 **9. References**

- 345 1. Smith JL, Schoenwolf GC. Neurulation: coming to closure. *Trends Neurosci.* Nov
346 1997;20(11):510-7. doi:10.1016/s0166-2236(97)01121-1
- 347 2. Manning SM, Jennings R, Madsen JR. Pathophysiology, prevention, and potential
348 treatment of neural tube defects. *Ment Retard Dev Disabil Res Rev.* 2000;6(1):6-14.
349 doi:10.1002/(SICI)1098-2779(2000)6:1<6::AID-MRDD2>3.0.CO;2-B
- 350 3. Oliver ER, Heuer GG, Thom EA, et al. Myelomeningocele sac associated with worse
351 lower-extremity neurological sequelae: evidence for prenatal neural stretch injury? *Ultrasound*
352 *Obstet Gynecol.* Jun 2020;55(6):740-746. doi:10.1002/uog.21891
- 353 4. Jeelani Y, McComb JG. Congenital hydrocephalus associated with myeloschisis. *Childs*
354 *Nerv Syst.* Oct 2011;27(10):1585-8. doi:10.1007/s00381-011-1560-4
- 355 5. Juriloff DM, Harris MJ. Insights into the Etiology of Mammalian Neural Tube Closure
356 Defects from Developmental, Genetic and Evolutionary Studies. *J Dev Biol.* Aug 21
357 2018;6(3)doi:10.3390/jdb6030022
- 358 6. Meuli M, Meuli-Simmen C, Hutchins GM, et al. In utero surgery rescues neurological
359 function at birth in sheep with spina bifida. *Nat Med.* Apr 1995;1(4):342-7.
- 360 7. Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal
361 repair of myelomeningocele. *N Engl J Med.* Mar 17 2011;364(11):993-1004.
362 doi:10.1056/NEJMoa1014379
- 363 8. Moldenhauer JS, Adzick NS. Fetal surgery for myelomeningocele: After the
364 Management of Myelomeningocele Study (MOMS). *Semin Fetal Neonatal Med.* Dec
365 2017;22(6):360-366. doi:10.1016/j.siny.2017.08.004
- 366 9. Kabagambe SK, Jensen GW, Chen YJ, Vanover MA, Farmer DL. Fetal Surgery for
367 Myelomeningocele: A Systematic Review and Meta-Analysis of Outcomes in Fetoscopic versus
368 Open Repair. *Fetal Diagn Ther.* Sep 15 2017;doi:10.1159/000479505
- 369 10. Corroenne R, Sanz Cortes M, Johnson RM, et al. Impact of the cystic neural tube
370 defects on fetal motor function in prenatal myelomeningocele repairs: A retrospective cohort
371 study. *Prenat Diagn.* Jul 2021;41(8):965-971. doi:10.1002/pd.5992
- 372 11. Corroenne R, Yopez M, Pyarali M, et al. Prenatal predictors of motor function in children
373 with open spina bifida: a retrospective cohort study. *BJOG: An International Journal of*
374 *Obstetrics & Gynaecology.* 2021;128(2):384-391. doi:https://doi.org/10.1111/1471-0528.16538
- 375 12. Brock CO, Bergh EP, Fishel Bartal M, et al. The significance of hindbrain herniation
376 reversal following prenatal repair of neural tube defects. *J Neurosurg Pediatr.* Jul 1
377 2023;32(1):106-114. doi:10.3171/2023.2.Peds22457
- 378 13. Nagaraj UD, Bierbrauer KS, Zhang B, Peiro JL, Kline-Fath BM. Hindbrain Herniation in
379 Chiari II Malformation on Fetal and Postnatal MRI. *AJNR Am J Neuroradiol.* May
380 2017;38(5):1031-1036. doi:10.3174/ajnr.A5116
- 381 14. Backley S, Bergh E, Garnett J, et al. Fetal cardiovascular changes during open and
382 fetoscopic in-utero spina bifida closure. *Ultrasound in Obstetrics & Gynecology.*
383 n/a(n/a)doi:https://doi.org/10.1002/uog.27579
- 384 15. Danzer E, Johnson MP, Wilson RD, et al. Fetal head biometry following in-utero repair of
385 myelomeningocele. *Ultrasound Obstet Gynecol.* Nov 2004;24(6):606-11. doi:10.1002/uog.1780
- 386 16. Tortori-Donati P, Rossi A, Cama A. Spinal dysraphism: a review of neuroradiological
387 features with embryological correlations and proposal for a new classification. *Neuroradiology.*
388 Jul 2000;42(7):471-91. doi:10.1007/s002340000325
- 389 17. Papanna R, Fletcher S, Moise KJ, Jr., Mann LK, Tseng SC. Cryopreserved Human
390 Umbilical Cord for In Utero Myeloschisis Repair. *Obstet Gynecol.* Aug 2016;128(2):325-30.
391 doi:10.1097/AOG.0000000000001512

- 392 18. Farmer DL, Thom EA, Brock JW, 3rd, et al. The Management of Myelomeningocele
393 Study: full cohort 30-month pediatric outcomes. *Am J Obstet Gynecol*. Feb 2018;218(2):256 e1-
394 256 e13. doi:10.1016/j.ajog.2017.12.001
- 395 19. Babcock CJ, Goldstein RB, Barth RA, Damato NM, Callen PW, Filly RA. Prevalence of
396 ventriculomegaly in association with myelomeningocele: correlation with gestational age and
397 severity of posterior fossa deformity. *Radiology*. Mar 1994;190(3):703-7.
398 doi:10.1148/radiology.190.3.8115615
- 399 20. Zou J, Wang F, Yang X, et al. Association between rare variants in specific functional
400 pathways and human neural tube defects multiple subphenotypes. *Neural Dev*. Jul 10
401 2020;15(1):8. doi:10.1186/s13064-020-00145-7
- 402 21. Au KS, Hebert L, Hillman P, et al. Human myelomeningocele risk and ultra-rare
403 deleterious variants in genes associated with cilium, WNT-signaling, ECM, cytoskeleton and cell
404 migration. *Sci Rep*. Feb 11 2021;11(1):3639. doi:10.1038/s41598-021-83058-7
- 405 22. Tian T, Lei Y, Chen Y, et al. Somatic mutations in planar cell polarity genes in neural
406 tissue from human fetuses with neural tube defects. *Hum Genet*. Oct 2020;139(10):1299-1314.
407 doi:10.1007/s00439-020-02172-0
- 408 23. Galea GL, Maniou E, Edwards TJ, et al. Cell non-autonomy amplifies disruption of
409 neurulation by mosaic *Vangl2* deletion in mice. *Nat Commun*. Feb 19 2021;12(1):1159.
410 doi:10.1038/s41467-021-21372-4
- 411 24. White M, Arif-Pardy J, Connor KL. Identification of novel nutrient-sensitive gene
412 regulatory networks in amniocytes from fetuses with spina bifida. *Reprod Toxicol*. Mar
413 2023;116:108333. doi:10.1016/j.reprotox.2022.12.010

414


415 **10. Figure Legends**

416 **Figure 1. Morphometric classification of spina bifida lesions.** Using high-resolution
417 fetoscopic images and videos obtained during surgery, we distinguished five lesion types based
418 on stretching of the nerve roots and exposure of the neural placode. The table presents the key
419 findings used to distinguish the category based on the visual characteristics observed in the
420 fetoscopic view. The illustrations show the 5 types, demonstrating the differences in nerve root
421 stretching and placode exposure to amniotic fluid (– *Blue line*: dura mater; – *Green line*:
422 arachnoid layer; – *Black line*: pia mater; – *Pink line*: skin layer; *Yellow color*: Spinal cord and
423 nerve roots; L: lumbar vertebra; S: sacral vertebra). Two rows of ultrasound images present
424 (Top) transverse images at the mid-lesion and (Bottom) midline sagittal images of the lesion by
425 lesion type. Yellow dotted arrows indicate the neural placode with dorsal displacement/ectopia
426 from the vertebral canal. Two rows of fetoscopic images present lesions (Top) before and
427 (Bottom) after dissection by lesion type. White dotted arrows indicate stretching nerve roots.

428 **Figure 2. Fetal head biometry differs by lesion type at baseline evaluation and changes**
429 **after fetal surgery.** Box plots compare fetal (**A-C**) head circumference (HC) percentile, (**D-F**)
430 largest ventricle size, and (**G-I**) Cortical Index (CI) by lesion type at preoperative evaluation (**A**,
431 **D, G**) and at delivery (**B, E, H**) and show the change between timepoints (**C, F, I**). CI was
432 calculated as HC (in mm) divided by ventricle size (in mm). Within each box, horizontal bold
433 black lines denote median values; boxes extend from the 25th to the 75th percentile of each
434 group's distribution of values; vertical extending lines denote adjacent values (i.e., the most
435 extreme values within 1.5 interquartile range of the 25th and 75th percentile of each group);
436 dots denote observations outside the range of adjacent values. * $p < 0.05$, ** $p < 0.01$.


437

438 **Figure 1. Morphometric classification of spina bifida lesions.**



439
440

441 **Figure 2. Fetal head biometry differs by lesion type at baseline evaluation and changes**
442 **after fetal surgery.**



443
444

445 **11. Tables**446 **Table 1. Maternal demographics and preoperative characteristics by lesion type.**

Variables	All (n=57)	Type 1 (n=8)	Type 2 (n=22)	Type 3 (n=9)	Type 4 (n=8)	Type 5 (n=10)	P-value
Maternal age (years)	29.9 (19, 44)	29.8 (22, 35)	28.5 (21, 44)	30.2 (19, 38)	30.3 (22, 35)	26.9 (21, 34)	0.380
Gravidity	2.2 (1, 7)	1.8 (1, 5)	1.8 (1, 4)	2.7 (1, 4)	2.6 (1, 7)	2.4 (1, 5)	0.160
Parity	0.8 (0, 4)	0.3 (0, 1)	0.5 (0, 2)	1.3 (0, 3)	1.4 (0, 4)	0.9 (0, 2)	0.066
Body Mass Index	29.6 (19.7, 45)	32.2 (21.8, 42.1)	29.4 (22.0, 38.4)	29.9 (22.6, 45.2)	30.5 (19.7, 42.7)	27.0 (19.7, 35.9)	0.560
GA at evaluation	23.6 (21.0, 25.6)	23.6 (23.1, 23.9)	23.6 (21.1, 25.6)	23.0 (21.0, 24.6)	23.7 (21.1, 24.9)	24.1 (23.0, 25.3)	0.110
EFW (g)	744 (581, 1050)	788 (643, 1050)	759 (597, 1016)	736 (585, 953)	717 (623, 814)	704 (581, 830)	0.57
Biparietal Diameter (mm)	55.5 (47, 67.8)	57 (52, 65.3)	56.8 (49.7, 67.6)	55.4 (50.3, 67.8)	54.1 (49, 57.4)	52.7 (47, 56.2)	0.12
Head Circ. (mm)	214 (184, 257)	217 (192, 243) ^{ab}	220 (195, 252) ^b	214 (195, 257) ^{ab}	206 (184, 224) ^a	203 (191, 222) ^a	0.03
Abdom. Circ. (mm)	206 (185, 233)	210 (193, 233)	207 (190, 228)	205 (188, 226)	205 (188, 217)	204 (185, 224)	0.9
Femur length (mm)	44.9 (39.5, 51.4)	46.2 (43.3, 50.7)	45.6 (41.4, 49.6)	45.0 (41.3, 51.4)	43.6 (39.5, 46.8)	43.3 (39.7, 46.1)	0.084
Lesion Anterior-Posterior Dimension (cm)	1.4 (0.1, 3.8)	2.6 (1.6, 3.8) ^a	1.8 (1.1, 2.7) ^b	1.0 (0.6, 1.5) ^c	0.6 (0.1, 1.0) ^{cd}	0.5 (0.3, 0.9) ^d	< 0.001
Lesion Maximum Width (cm)	2.2 (0.9, 5.4)	3.6 (2.3, 5.4) ^a	2.4 (1.3, 3.4) ^b	2.0 (1.6, 2.6) ^c	1.6 (1.2, 2.4) ^d	1.3 (0.9, 2.0) ^d	< 0.001
Lesion Vertical Length (cm)	2.6 (0.3, 5.5)	3.6 (2.4, 5.5) ^a	2.7 (1.6, 3.9) ^b	2.1 (1.4, 3.5) ^c	2.3 (0.3, 4.1) ^{bc}	2.4 (0.9, 3.3) ^{bc}	0.006
Lesion Volume (cm ³)	6.2 (0.1, 59.6)	21.6 (5.3, 59.6) ^a	6.3 (2.2, 12.4) ^b	2.3 (1.0, 4.8) ^c	1.4 (0.1, 5.3) ^{cd}	0.9 (0.1, 2.6) ^d	< 0.001
Right ventricle (mm)	11.0 (5.0, 21.0)	9.3 (5.1, 13.7) ^a	12.8 (6.8, 21.0) ^b	11.3 (5.0, 20.2) ^{ab}	8.0 (5.8, 11.4) ^a	10.3 (7.0, 13.4) ^{ab}	0.017
Left ventricle (mm)	11.8 (5.3, 23.8)	9.5 (6.3, 14.5) ^a	13.7 (8.2, 21.3) ^b	11.8 (5.3, 23.8) ^{ab}	9.5 (6.5, 14.9) ^a	11.2 (7.2, 13.7) ^a	0.006
Largest ventricle (mm)	12.1 (6.7, 23.8)	10.2 (7.7, 14.5) ^a	14.0 (8.2, 21.3) ^b	12.4 (6.7, 23.8) ^{ab}	9.7 (7.2, 14.9) ^a	11.2 (7.2, 13.7) ^a	0.008
Level of Lesion							0.831
L2 & above	6 (11%)	0 (0%)	2 (9%)	1 (11%)	2 (25%)	1 (10%)	

Variables	All (n=57)	Type 1 (n=8)	Type 2 (n=22)	Type 3 (n=9)	Type 4 (n=8)	Type 5 (n=10)	P-value
L3-L4	31 (54%)	5 (63%)	11 (50%)	4 (44%)	5 (63%)	6 (60%)	
L5-S1	20 (35%)	3 (38%)	9 (41%)	4 (44%)	1 (13%)	3 (30%)	
Tonsillar herniation							0.005
Foramen magnum	20 (35%)	7 (88%)	10 (46%)	2 (22%)	1 (13%)	0 (0%)	
C1-C2	22 (39%)	1 (13%)	9 (41%)	4 (44%)	3 (38%)	5 (50%)	
C3-C4	14 (25%)	0 (0%)	3 (14%)	3 (33%)	4 (50%)	4 (40%)	
Not documented	1 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (10%)	
No movement knee	5 (9%)	2 (25%)	2 (9%)	1 (11%)	0 (0%)	0 (0%)	0.353
No movement ankles	10 (18%)	2 (25%)	4 (18%)	3 (33%)	1 (13%)	0 (0%)	0.350
No movement hip	1 (2%)	0 (0%)	1 (5%)	0 (0%)	0 (0%)	0 (0%)	1.000
Presence of Talipes	12 (21%)	2 (25%)	5 (23%)	2 (22%)	1 (13%)	2 (20%)	1.000

447 Data are presented as mean (range) by Kruskal-Wallis test; or as n (%) by Fisher's exact test. Groups with a different letter (a, b, c or d) are significantly different
448 from each other ($p < 0.05$). Abdom. Circ., abdominal circumference; EFW, estimated fetal weight; GA, gestational age; Head Circ., head circumference.
449

450 **Table 2. Linear regression analysis of factors associated with preoperative ventricle size.**

Independent Variables	Beta	Standard Error	t-Value	P-Value
Lesion Type 1	0.664	1.877	0.35	0.7252
Lesion Type 2	3.959	1.432	2.76	0.0080
Lesion Type 3	1.960	1.599	1.23	0.2261
Lesion Type 4	-1.641	1.652	-0.99	0.3253
Lesion Level	-1.371	0.743	-1.84	0.0712
Tonsillar Herniation	0.896	0.717	1.25	0.2174

451 All lesion types are compared with lesion Type 5.

452

453 **Table 3. Postoperative and neonatal outcomes by lesion type.**

Variables	All (n=57)	Type 1 (n=8)	Type 2 (n=22)	Type 3 (n=9)	Type 4 (n=8)	Type 5 (n=10)	P-value
GA at Surgery (wks)	25.3 (24.1, 26.0)	25.2 (24.7, 25.7)	25.3 (24.1, 26.0)	25.1 (24.3, 25.9)	25.4 (24.6, 25.9)	25.2 (24.1, 26.0)	0.480
Fetal surgery time (mins)	131.8 (48, 209)	128.5 (48, 209)	133.9 (92, 171)	126.7 (90, 162)	127.3 (49, 172)	137.7 (97, 193)	0.960
Need for skin patch closure	18 (32%)	2 (25%) ^a	2 (9%) ^a	1 (11%) ^a	3 (38%) ^a	10 (100%) ^b	< 0.001
PPROM	17 (30%)	5 (63%)	5 (23%)	3 (33%)	2 (25%)	2 (20%)	0.314
GA at Delivery (wks)	34.9 (25.4, 39.4)	32.4 (28.7, 34.9) ^a	36 (32.7, 39) ^b	35.9 (33, 39.4) ^{b,c}	33.1 (25.4, 37.4) ^{a,c}	35 (31, 38.7) ^{b,c}	0.01
Spontaneous / Indicated delivery							0.758
Spontaneous	24 (42%)	4 (50%)	10 (45%)	2 (22%)	4 (50%)	4 (40%)	
Indicated	33 (58%)	4 (50%)	12 (55%)	7 (78%)	4 (50%)	6 (60%)	
CSF leakage at birth	0/55 (0%)	0 (0%)	0/21 (0%)	0/8 (0%)	0 (0%)	0 (0%)	
Wound revision	6/55 (11%)	0 (0%)	1/21 (5%)	1/8 (13%)	2 (25%)	2 (20%)	0.321
CSF diversion NICU	9/55 (16%)	0 (0%)	6/21 (29%)	1/8 (13%)	1 (13%)	1 (10%)	0.467
NICU length of stay (days)	27.5 (0, 122)	40.4 (17, 71)	17.8 (0, 44)	17.8 (3, 44)	50.4 (12, 122)	26.8 (14, 33)	< 0.001

454 Data are presented as mean (range) by Kruskal-Wallis test or as n (%) by Fisher's exact test. Groups with a different letter (a or b) are significantly different from
455 each other (p < 0.05). CSF, cerebrospinal fluid; GA, gestational age; NICU, neonatal intensive care unit; PPRM, preterm premature rupture of membranes.

456